Innova launches nano-gold antibody tech; Imprimis snags delivery compound for eye surgery recovery;

> Innova Biosciences launched its site-specific bioconjugation technology for attaching antibodies to gold nanoparticles with more control over the orientation of the antibodies. More

> Imprimis Pharmaceuticals ($IMMY) acquired a compound for the delivery of anti-inflammatory and antibacterial agents into the eye. Release

> Arena Pharmaceuticals ($ARNA) completed a Phase I trial of its oral prostacyclin receptor agonist APD811 for the treatment of arterial hypertension. The company plans to begin Phase II in the beginning of 2014. Release

> Mallinckrodt ($MNK) said it would present clinical data next week on its extended-release oral oxycodone and acetaminophen formulation MNK-795 at PAINWeek 2013 in Las Vegas. Release

> Orexo reported successful results from a Phase II study of its sublingual formulation of alfentanil, a pain management drug for surgical and invasive diagnostic procedures. Release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.